An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will discuss their first quarter 2024 financial results and provide business updates on May 8, 2024. The conference call and webcast are scheduled for 8:30 a.m. ET. Investors can access the call by dialing the provided numbers or by visiting the Seres website. A replay will be available on the website for 21 days.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates.
To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5686561. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation. For more information, please visit www.serestherapeutics.com.
When will Seres Therapeutics announce their first quarter 2024 financial results?
Seres Therapeutics will announce their first quarter 2024 financial results on May 8, 2024.
How can investors access the conference call?
Investors can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) and referencing the conference ID number 5686561.
Where can investors find the live webcast of the event?
Investors can find the live webcast in the 'Investors and News' section of the Seres website at www.serestherapeutics.com.
How long will the webcast replay be available?
The webcast replay will be available on the Seres website for approximately 21 days after the event.
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
